Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514


Delayed Quote. Delayed  - 12/02 05:28:17 pm
11.18 EUR   +0.27%
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
News SummaryMost relevantAll newsSector news 


share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2012 | 05:40pm CET


Longjumeau, february 22, 2012

In millions of euros
Net sales158,5  164,5  
including Pharmaceutical Synthesis99,4  102,1  
Including Fine Speciality Chemicals59,1  62,4  
EBITDA (*)16,1  16,5  
EBITDA margin10,2%10,0%
Current Operating Income (*)3,4  5,4  
Other Operating income and expense-2,2  -1,7  
Financial Result-4,2  -3,6  
Taxes (**)-0,9  -3,1  
Share of profit/loss of associates-0,1  0,2  
Net Result-4,0  -2,8  
Net Result (exluding depreciation of deferred tax asset)-4,0  0,2  
Equity71,6  69,2  
Net debt47,5  53,6  
Gearing0,66  0,77  
Net asset per share5,2  5,1  
(*) of which research tax credit (CIR): 2.8 million euros in 2011 and 2.7 in 2010
(**) including a depreciation of deferred tax asset for an amount of 3 M€ in 2011
Audit procedures have been performed and auditor's report is in progress of being issued.

PCAS Group consolidated turnover was up 3.8% in 2011 compared with 2010.

Pharmaceutical Synthesis
Business was affected during the first five months of the year by the lower planned contribution from the new contract between PCAS and Sanofi, in force as of May 31, 2010. apart from this contract, Exclusive and Generics  Pharma business rose 13.1% in 2011.
Fine Speciality Chemicals
Fine Speciality Chemicals reported growth of 5.6% in 2011.

Current Operating Income rose 60% to 5.4 million euros in 2011, compared with 3.4 million euros in 2010.

Net profit in 2011 was affected by a non recurring depreciation of deferred tax assets of 3 million euros (without any effect on cash), due to the effects of the French Goverment amending tax law for 2011 relating to the conditions for future use of loss carry forwards.

Excluding this non recurring item, net profit for 2011 stood at 0.2 million euros compared with (-4) million euros in 2010.

Net debt was 53.6 million euros as of December 31, 2011, compared with 47.5 million euros as of December 31, 2010, resulting from the increase in the working capital , due in particular to strong growth in turnover in the fourth quarter of 2011, as well as research tax credits, which are only refundable after a 3 years period.

To successfully implement the Group's development strategy, which is based on increasing the share of proprietary products and expanding differentiating technologies, the Board of Directors has asked the Group General Management to focus its action in 2012 on improving profitability and level of working capital.

Next meeting: 2012 Shareholder's Meeting at 9 .a.m. on April 24, 2012, in Longjumeau

About PCAS
PCAS is a fine and speciality chemicals Group that shares an ambition of excellence with its clients.  This client base comprises mainly international groups which are leaders in their markets.  PCAS designs and delivers the best industrial solutions to the specific expectations of its clients.  These wide-ranging expectations share in common a demand for safety, quality, competitiveness, innovation and sustainability.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PCAS
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
11/03 PCAS : net sales as of 30 September, 2016
09/14 PCAS : ex-dividend day for interim dividend
09/07 PCAS : 1st half 2016 earnings report continued organic growth
09/02PCAS : half-yearly earnings release
07/19 PCAS : Net sales for the 1st half of 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Financials (€)
Sales 2016 194 M
EBIT 2016 17,3 M
Net income 2016 9,85 M
Debt 2016 35,6 M
Yield 2016 1,48%
P/E ratio 2016 15,53
P/E ratio 2017 13,39
EV / Sales 2016 1,06x
EV / Sales 2017 1,00x
Capitalization 169 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 2
Average target price 12,6 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results